Accelerating advanced cell therapy research and treatments

Scaling up, to reduce the price

Advanced cell therapies will disrupt health care as we know it. Application opportunities are almost limitless. However, there is a shortage of cells manufactured according to full Good Manufacturing Practice (GMP) compliance on the global market – both for clinical trials and treatments. That's why Cellcolabs was founded in 2021.

---

Cellcolabs is a biotech company specializing in industrial GMP production of high quality stem cells (mesenchymal stromal cells) in order to make them available at scale. Our ultimate goal is to accelerate stem cell research and make the treatments of the future available for all.

Based on 20 years experience

Cellcolabs builds on the findings and clinical experience from more than 20 years of stem cell research at Karolinska Institutet. World renowned stem cell professor Katarina Le Blanc with research group has published 167 scientific papers with 30 000 citations (as of 2021), resulting in exceptional MSC quality. The MSC are derived from bone marrow and have been MPA approved for use in two academic clinical trials in Sweden, with more clinical trials to come. Cellcolabs currently provides a research grade version and is planning to provide a GMP version of the cells.

Order cells

Application opportunities are almost limitless

Through their regenerative, immunomodulatory and anti-inflammatory effects, mesenchymal stromal cells (MSC) have the potential to cure or prevent many chronic diseases. They are believed to primarily work through close interaction with other cells through cell-to-cell signalling.

MSC have the potential to cure or prevent many conditions and chronic diseases. Research is conducted within the following fields, among many others.